Cambridge, England, 2017-Feb-14 — /EPR Network/ — Resveratrol and lycopene are the compounds known for anti-ageing and cardio-protective properties. Mediterranean diet based, among others, on consumption of big quantities of lycopene-rich vegetables coincides with a longer lifespan, lower incidence of CVDs and reduced occurrence of some forms of cancer among the population of Mediterranean region. High resveratrol consumption is considered a factor in “French Paradox”, where epidemiological data show low incidence of CVDs, despite high consumption of saturated fats. Consumers have enormous choice of food supplements including lycopene and resveratrol, but key information is often missing: what happens to the substance once consumed and how much of it is really absorbed?
The GenQual proprietary real-time PCR platform, when applied to the genes that are involved in the manifestation of several autoimmune diseases, allows us to detect and assess single nucleotide polymorphisms. Here, allelic determination is used as potential predictor of the treatment response by the novel anti-IL6 antibody, which is currently in development by R-Pharm.
Long Island City, New York, January 15, 2016 — /EPR NETWORK/ — Thursday of this week (January 14, 2016), BOC Sciences officially launched its analytical support service, aiming to provide all-round custom services on the base of its present services in pharmaceutical field.
The analytical service of BOC Sciences covers a wide range in almost every aspect of drug discovery from impurities identification, purity level testing, to right equipment suggestion for compound preparation with the aim of providing the best solutions for research conduction and maximizing the outcome with less waste in both time and cost.
WILMINGTON, DE, June 18, 2015 — /EPR NETWORK/ — M. Davis, the fifth generation woman-owned Industrial Contractor and Fabricator headquartered in Wilmington, DE has named Christina MacMillan its Manager of Supplier Diversity. Christina MacMillan will enhance the program by working with diverse vendors to help identify opportunities with M. Davis. This will enable M. Davis to continue promoting economic growth and community development through our diversity and inclusion initiatives while also expanding our current supplier base to include the best and brightest.
Released on: December 18, 2014, 12:59 pm (EST)
Author: Experimentica Ltd.
Kuopio, Finland, December 18, 2014 — /EPR NETWORK/ — The Lions Eye Institute (LEI) and Experimentica Ltd., a global ophthalmic contract research organization (CRO) announced today that they have entered into an exclusive license agreement for the Akimba mouse model for diabetic retinopathy for contract research. The license agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.
Toronto, Canada, December 01, 2014 — /EPR NETWORK/ — ViroCarb Inc. has launched a worldwide crowd funding campaign to promote the development of its new HIV infection inhibitor.
WORLD AIDS DAY – Make a donation to save lives from AIDS! Support new treatment development at: https://www.indiegogo.com/projects/funding-a-new-therapy-against-drug-resistant-hiv/x/9240077
Despite the great progress made in HIV/AIDS treatment, there is still an urgent need for new drugs, particularly for people who have had to abandon existing treatments due to HIV drug resistance and side effects.
Shanghai, May 28, 2014 — /EPR NETWORK/ — HD Biosciences Co., Ltd. (HDB) and E. J. Corey Institute of Biomedical Research (CIBR) announced that they have reached a risk-sharing agreement on collaborative drug discovery and development in the therapeutic areas of infectious diseases, metabolic diseases, and oncology. This joint effort will focus on both international and Chinese markets to provide innovative medicines for unmet healthcare needs. The agreement includes lead candidate selection pre-clinical development, IND filing, clinical trials, and NDA approvals. Both companies will share financial returns from any successes or products launches.
Released on: November 20, 2013, 1:10 pm
Author: TCG Lifesciences Limited
November 20, 2013, 1:10 pm — /EPR NETWORK/ — Axcellerate Pharma establishes CMO/CRO and API manufacturing facility in New Jersey, US. Focus will be small molecule and biologics PR&D, innovative technology platforms, filling vial and bag operations, peptide synthesis, oligonucleotide production and related areas.
October 28, 2013, 10:18 am — /EPR NETWORK/ — HD Biosciences Co., Ltd (HDB) and Anchor Therapeutics, Inc. today announced that they have formed a strategic collaboration to co-develop and co-market Anchor’s proprietary pepducin technology and provide novel drug development solutions to global pharmaceutical companies with drug discovery efforts focused on G-protein coupled receptors (GPCR).
Biosortia Pharmaceuticals Hires Kurt Dieck as President and CEO to Accelerate Strategy to Develop and License New Highly Active Compounds from Unculturable Aquatic Microbial Consortia
Dublin, Ohio, January 22, 2013, 11:46 am — /EPR NETWORK/ — Kurt Dieck formerly SVP of Strategy and Business Execution at Cardinal Health, will lead early stage drug discovery business at Biosortia Pharmaceuticals. Dieck was named President and CEO in November 2012 and has quickly identified other key executives, including Dr. Guy Carter, former Natural Product head at Wyeth Pharmaceuticals, as his Chief Science Officer. In conjunction, other collaboration partners have joined the team, including NOAA (National Oceanic and Atmospheric Administration), NCI (National Cancer Institute) and key universities, to strategically accelerate the development of novel drug leads in the therapeutic areas of cancer, infectious diseases, inflammation and neurological disorders. Biosortia Pharmaceuticals has seen promising early results with dozens of novel compounds having already been requested, and are under evaluation with NCI and Eli Lilly.